Pavel Bogomolov
Overview
Explore the profile of Pavel Bogomolov including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
261
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asselah T, Lampertico P, Aleman S, Bourliere M, Streinu-Cercel A, Bogomolov P, et al.
Liver Int
. 2024 Dec;
45(4):e16174.
PMID: 39648559
Background And Aims: The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients...
2.
Alboraie M, Tanwandee T, Xu X, Nikolova D, Estupinan E, Ghazinyan H, et al.
Ann Hepatol
. 2024 Oct;
29(6):101573.
PMID: 39477629
No abstract available.
3.
Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pantea V, et al.
N Engl J Med
. 2024 Jun;
391(2):133-143.
PMID: 38842520
Background: In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label...
4.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
J Hepatol
. 2024 May;
81(4):621-629.
PMID: 38734383
Background & Aims: Bulevirtide (BLV), a first-in-class entry inhibitor, is approved in Europe for the treatment of chronic hepatitis delta (CHD). BLV monotherapy was superior to delayed treatment at week...
5.
Pabon-Carrasco M, Keco-Huerga A, Castro-Fernandez M, Saracino I, Fiorini G, Vaira D, et al.
United European Gastroenterol J
. 2023 Dec;
12(1):122-138.
PMID: 38050339
Background: Management of Helicobacter pylori (H. pylori) infection requires co-treatment with proton pump inhibitors (PPIs) and the use of antibiotics to achieve successful eradication. Aim: To evaluate the role of...
6.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al.
N Engl J Med
. 2023 Jun;
389(1):22-32.
PMID: 37345876
Background: Coinfection with hepatitis D virus (HDV) accelerates the progression of liver disease associated with chronic hepatitis B. Bulevirtide inhibits the entry of HDV into hepatocytes. Methods: In this ongoing...
7.
Wedemeyer H, Schoneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al.
Lancet Infect Dis
. 2022 Sep;
23(1):117-129.
PMID: 36113537
Background: Bulevirtide is a first-in-class peptidic entry inhibitor for hepatitis B virus (HBV) and hepatitis D virus infection. In July, 2020, bulevirtide 2 mg received conditional marketing authorisation by the...
8.
Caldas M, Perez-Aisa A, Tepes B, Keco-Huerga A, Bujanda L, Lucendo A, et al.
Antibiotics (Basel)
. 2021 Aug;
10(8).
PMID: 34439015
Statins could increase the effectiveness of eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life....
9.
Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al.
J Hepatol
. 2016 May;
65(3):490-8.
PMID: 27132170
Background & Aims: The therapeutic option for patients with chronic hepatitis delta virus infection (CHD) is limited to interferon alpha with rare curative outcome. Myrcludex B is a first-in-class entry...